Search

Displaying results 511 - 520 of 4626 in total
  1. Drug

    Acetarsol

    go.drugbank.com/drugs/DB13268
    ApprovedWithdrawn

    [L2622] It was first discovered in 1921 by Ernest Fourneau at the Pasteur Institute. It was developed by Neolab Inc, and approved by Health Canada as an antifungal on December 31, 1964.

  2. Drug

    Glecaprevir

    go.drugbank.com/drugs/DB13879
    ApprovedInvestigational

    It demonstrates a high genetic barrier against resistance mutations of the virus. … Mavyret is also indicated for HCV genotype 1-infected patients who have been previously treated with regimens either containing an NS5A inhibitor or an NS3/4A protease inhibitor, but not both [L940].

  3. Drug

    Idebenone

    go.drugbank.com/drugs/DB09081
    ApprovedInvestigational

    Due to its biochemical mode of action, it's thought that idebenone may re-activate viable-but-inactive retinal ganglion cells (RGCs) in LHON patients [L885]. … It is not currently approved for use by either the Food and Drug Administration (USA) or Health Canada.

  4. Drug

    Efanesoctocog alfa

    go.drugbank.com/drugs/DB16662
    ApprovedInvestigational

    Endogenous VWF protects FVIII from degradation but also sets a half-life of approximately 15 to 19 h. … [L45379] The use of FVIII replacement products is beneficial in patients with hemophilia A; however, their quality of life can be affected due to frequent doses.

  5. Drug

    Ebola Zaire vaccine (live, attenuated)

    go.drugbank.com/drugs/DB15595
    ApprovedInvestigational

    [L10854] Ebola virus disease, formerly known as Ebola hemorrhagic fever, is a rare but severe and often deadly disease. … In December 2019, Ervebo was approved by the FDA in the United States.

  6. Drug

    Nafcillin

    go.drugbank.com/drugs/DB00607
    ApprovedInvestigational

    It is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strains that are resistant to other penicillins, except those caused by MRSA.

  7. Drug

    Eflapegrastim

    go.drugbank.com/drugs/DB15001
    ApprovedInvestigational

    [L43135] In September 2022, eflapegrastim was approved by the US FDA as a prophylactic against infection, as manifested by febrile neutropenia, in patients receiving certain myelosuppressive anti-cancer … the use of pharmacologic prophylaxis against FN in patients receiving high-risk regimens and those receiving intermediate-risk regimens who have ≥1 additional risk factor.

  8. Drug

    Elapegademase

    go.drugbank.com/drugs/DB14712
    Approved

    [F1937] Elapegademase is generated in _E. coli_, developed by Leadiant Biosciences and FDA approved on October 5, 2018.[L4654,F1939]

  9. Drug

    Bicisate

    go.drugbank.com/drugs/DB11164
    Approved

    [A32374] The complex of bicisate and technetium Tc99m as a kit was developed by Lantheus Medcl and FDA-approved on November 23, 1994.[L2029]

  10. Drug

    Risperidone

    go.drugbank.com/drugs/DB00734
    ApprovedInvestigational

    [L12885] Risperidone binds with a very high affinity to 5-HT2A receptors, approximately 10-20 fold greater than the drug's binding affinity to D2 receptors, and carries lesser activity at several off-targets … [L12885] Schizophrenia and various mood disorders are thought to be caused by an excess of dopaminergic D2 and serotonergic 5-HT2A activity, resulting in overactivity of central mesolimbic pathways